How Clay Siegall Is Changing The Way Doctors Treat Cancer

A Key Breakthrough
Cancer is one of the world’s most devastating diseases. It will kill nearly a third of all living people and generate billions of dollars in medical costs. There is a serious need for new and effective treatment options for cancer patients. One of the greatest researchers in this field is Clay Siegall. With more than 18 years as the head of Seattle Genetics he has made some of the biggest breakthroughs in chemotherapy. In particular he has found a way to fuse antibodies and anticancer drugs to improve the treatment of cancer with fewer side effects. As this approach has become more popular investors are flocking to Seattle Genetics. As his unique approach to fighting cancer becomes more popular Seattle Genetics will rake in millions of dollars in revenue.

The Science Behind Seattle Genetics
The core of Siegall’s latest project is combining antibodies and drugs to create ADC or antibody-drug conjugates. ADCs provide a faster platform for distribution of drugs but the addition of antibodies means the patient’s body is less likely to resist the treatment. This personalized approach to treatment is focused on giving every patient a treatment specifically for them.

Before Siegall created the ADC he had already made a name for himself in the 90s as a cancer researcher. Between the years 1991 and 1997 he worked for the Bristol-Myers Squibb Pharmaceutical Research Institute. Here he researched various cancers and the possible treatments that may allow physicians to treat afflicted patients. After leaving the ADC he went on to found Seattle Genetics where much of his research finally came to fruition. Currently Siegall works to secure deals with some of the biggest names in pharmaceuticals such as Pfizer. Through these deals he hopes to distribute his treatment options to the world on a larger scale.

Leave a Reply